Posted by Michael Wonder on 24 Nov 2022
Luspatercept for the treatment of patients with anaemia caused by myelodysplastic syndrome
24 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of luspatercept in the NHS in England.
NICE is unable to make a recommendation on the use of luspatercept for the treatment of patients with anaemia caused by myelodysplastic syndrome because BMS did not provide an evidence submission.
